Clinical Trials Logo
  1. Home
  2. Premenopausal Breast Cancer
  3. NCT03209518

Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"

Premenopausal Breast Cancer Clinical Trial

Official title:
Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"

Clinical Trial Summary

The purpose of this survey is to evaluate the safety in patients with premenopausal breast cancer receiving Leuprorelin in the routine clinical setting.

Clinical Trial Description

The drug being tested in this survey is called Leuprorelin for Injection Kit 22.5 mg. Leuprorelin is being tested to treat people who have premenopausal breast cancer.

This survey will look at the safety in patients with premenopausal breast cancer receiving the drug in the routine clinical setting.

The survey will enroll approximately 300 patients.

- Leuprorelin

This multi-center survey will be conducted in Japan. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03209518
Study type Observational
Source Takeda
Contact
Status Completed
Phase
Start date March 18, 2016
Completion date October 10, 2018
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01726322 - Ovarian Reserve in Premenopausal Breast Cancer
Terminated NCT02990845 - Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer Phase 1/Phase 2
Recruiting NCT05982093 - Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer Phase 2
Active, not recruiting NCT04997941 - Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients Phase 2
Not yet recruiting NCT05801705 - Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
Active, not recruiting NCT03407768 - Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer N/A
Recruiting NCT05720260 - Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC Phase 2
Recruiting NCT05333328 - OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk Phase 4
Not yet recruiting NCT06225284 - Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients Phase 2
Completed NCT01546649 - A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer Phase 3